Introduction
Polyamines are ubiquitous components of cells and are important for cell growth and viability (1). The absolute dependence of tumor cells on polyamines for growth and proliferation has led to their evaluation as a potential target for an-Technology in Cancer Research & Treatment, Volume 5, Number 6, December 2006 titumor treatment (2, 3) . Intracellular polyamine content is tightly regulated at the levels of biosynthesis, catabolism, uptake, and efflux. Polyamine metabolic pathways have been extensively studied (4) and compounds that inhibit polyamine metabolism have been developed and demonstrated to be effective for tumor growth suppression and prevention (3, 5) . Although inhibitors of the polyamine biosynthetic enzymes ornithine decarboxylase and S-adenosylmethionine decarboxylase are cytostatic in several cell lines and suppress tumorigenesis in vivo, such inhibition of polyamine biosynthesis can be overcome by the restoration of intracellular polyamine homeostasis via increased polyamine transport (1, 6) . Synthetic polyamine analogs can enter cells through a selective polyamine transport system and cause inhibition of tumor growth (7, 8) . Mechanisms by which polyamine analogs exert their intracellular effects include, but are not limited to, the induction of catabolism and the displacement of natural polyamines from functional sites related to the transcriptional regulation of genes (9) . A variety of classes of synthetic polyamine analogs have shown antineoplastic activity in a variety of tumor types. For example, N 1 , N11-bis (ethyl) norspermine (BENSpm) , which belongs to the class of symmetrically alkylated polyamine analogs, inhibits polyamine biosynthesis, decreases polyamine transport, and causes a significant induction of the polyamine catabolic enzyme spermidine/spermine N 1 acetyltransferase (SSAT) in several tumor models (10, 11) . BENSpm has been examined clinically in breast cancer patients (12) . Unsymmetrically substituted polyamine analogs, such as the bisalkylated tetraamine analog of spermine N1-ethyl-N11-[(cycloheptyl)methy]-4,8diazaundecane (CHENSpm) causes only a moderate induction of SSAT and exhibits potent growth-inhibitory effects against tumor cells with low activity of CHENSpm-detoxifying enzyme polyamine oxidase (PAO) (13, 14) .
A new generation of conformationally restricted polyamine analogs has been developed relatively recently (15) (16) (17) . In these compounds, the introduction of alicyclic residues or double bonds resulted in the restriction of free rotation in the central carbon chain of the molecule. The restriction of free rotation is thought to alter the ability of these analogs to bind DNA, tRNA or other polyamine-binding sites, potentially leading to the suppression of genes involved in neoplastic cell growth (16, 17) .
Several important growth-associated or cell cycle-associated genes or pathways have been reported to be affected by specific symmetrically or unsymmetrically substituted bis alkylpolyamine analogs (18) (19) (20) . However, little is known about the exact mechanisms by which conformationally restricted polyamine analogs induce antitumor activity. Information regarding CGC-11093 (formerly SLIL-11093) includes the fact that CGC-11093 is not efficient in inducing polyamine oxidase activity (PAOh1/SMO), an enzyme that oxidizes spermine and produces H 2 O 2 and that is inducible by other classes of polyamine analogs (21) . A recent study showed differential effects of three conformationally restricted polyamine analogs, CGC-11047, CGC-11093, and CGC-11158, against human breast cancer cell lines, and suggested specific cell line dependent mechanisms of action for each drug (22). CGC-11093 has been tested as an effective chemotherapeutic agent against a human prostate tumor xenograft grown in nude mice (23) . In this study we assessed the molecular effects of CGC-11093 against the human colon adenocarcinoma cell line, HCT116, by analyzing global changes in gene and protein expression as well as in DNA methylation and histone acetylation post treatment.
Materials and Methods

Chemicals and Reagents
All culture reagents were obtained from Invitrogen Corp. (Carlsbad, CA). An RNeasy kit was purchased from Qiagen Inc. (Valencia, CA) and a Reverse Transcription Kit was purchased from Promega Corp. (Madison, WI). Invitrogen Corp. synthesized all oligonucleotides used in the experiments. All reagents for real time RT-PCR were purchased from Applied Biosystems, Inc.(Foster City, CA). The acetylhistone H3 and H4 antibodies were purchased from Upstate Biotechnology (Lake Placid, NY).
CGC-11093
The polyamine analog CGC-11093 was obtained from Cellgate, Inc. (Redwood City, CA). CGC-11093 (3,8,13,18-tetraaza-10,11 -[(E)-1,2-cyclopropyl] eicosane tetrahydrochloride) is bis (ethyl) homospermine with a cyclopropyl ring in its central carbon chain (Figure 1 ). CGC-11093 was synthesized as described previously (16, 24) . CGC-11093 is highly water-soluble and a stock solution (10mM) was prepared in water, sterile-filtered, and stored at 20 ºC. Further dilutions were made in complete growth medium.
Cell Cultures
HCT116 colon adenocarcinoma cells were maintained in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% FBS and 1% penicillin/streptomycin.
MTT Assay
200 μl of cell suspensions containing 2,000 cells (0.01 × 10 6 cells/ml) were seeded in 96-well plates and treated with vari- 
Cell Viability
Cells were seeded at a concentration of 0.25 × 10 6 cells per 60 mm dish in media containing different concentrations of CGC-11093 (0.1, 1, 10, or 50 μM) and were collected seven days after subculture. The viability of control and analogtreated cells was evaluated by an automated Trypan blue dye exclusion method using a Beckman Coulter Vi-Cell™ Cell Viability analyzer (Beckman Coulter Inc, Miami, FL).
Isolation of Total RNA and Reverse Transcription
HCT116 cells were seeded in the absence or presence of CGC-11093 at either 1 μM or 10 μM for 72 h. Total cellular RNA was extracted according to a protocol supplied with the Qiagen RNeasy Kit. The experiment was performed three times with different cell passages (taken from passages 54-60). RNA samples were evaluated for integrity of 18S and 28S rRNA by ethidium bromide staining of 1 μg of RNA resolved by electrophoresis in a 1.0% agarose/formaldehyde gel. Reverse transcription was completed using a TaqMan Reverse Transcription Reagents Kit. Two μg of total RNA was transcribed into cDNA in a 100 μl reaction using Random hexamers and the recommended thermal conditions.
Microarray Analysis
Ten μg of total RNA was used to produce biotinylated cRNA that was hybridized to the Affymetrix GeneChip human genome U133 Plus 2.0 array according to the manufacturer's instructions (Affymetrix). Chips were washed and stained using a Fluidics Station (Affymetrix) and scanned with a Ge-neArray Scanner 3000 using default settings. Images from the scanned chips were quantitated to produce transcript level data using the Affymetrix Microarray Analysis Suite (MAS) 5.0. Transcript level data was loaded into GeneSpring 7.0 (Agilent Technologies) and normalized across arrays. Fold change was derived as the ratio of average differences from three experimental arrays as compared to three control arrays. Genes were selected based on analysis of variance (ANOVA) with variances not assumed equal (Welch's ANOVA) and a p-value of 0.05 adjusted for multiple testing using the Benjamini Hochberg false discovery rate method. A global error model based on replicates of the control and treated samples was used to estimate variance.
Quantitative Real-time RT-PCR
Real-time PCR amplification was performed with an ABI PRISM 7700 SDS instrument (Applied Biosystems), utilizing the universal thermal cycling conditions recommended by the Assay-on-Demand products protocol. Each 50 μl reaction included 25 μl of TaqMan Universal PCR master mix, 10 μl of the resulting cDNA from the reverse transcription step, and 15 μl diluted primer and probe mixes ordered from Assay-on-Demand products (Applied Biosystems, Foster City, CA). No template controls were included in each plate to monitor potential PCR contamination. The drug effect on target genes was tested in triplicate and each reaction was run in duplicate.
To determine the relative expression level of each target gene, the comparative C T method was used. The C T value of the target gene was normalized by the endogenous reference (ΔC T = C T(target) -C T(GAPDH) ) and compared with a calibrator (ΔΔC T = ΔC T(target) -ΔC T(calibrator) ). The first of three HCT116 replicates was designated as the calibrator sample in these experiments. The relative expression of each target gene was calculated via the Equation 2 -ΔΔCT . Data were presented as a ratio of the relative expression of each target gene in drug-treated cells to the expression of this gene in the first control replicate.
Proteomics Analysis
Seventy two hours after subculture, control, and CGC-11093 treated cells (10 μM) were lysed with a RIPA buffer, sonicated for 5-10 sec. and then incubated on ice for 30 min. Lysates were centrifuged at 13,000 rpm 4 ºC for 20 min. Supernatants were collected and cleaned using a ReadyPrep 2D Cleanup Kit (BioRad). Protein concentration was determined using a Bio-Rad D C protein assay (Bio-Rad Laboratories, Hercules, CA). Samples were analyzed by the Proteomics Facility Core (University of Arizona) using 2D PAGE gel electrophoresis (pI 5-8, 10-20% gradient). The gels were stained with silver, followed by in-gel digestion of spots expressed exclusively in one of the samples (control or CGC-11093). The samples were analyzed using nanoLC-MS/MS and SEQUEST database searching.
DNA Isolation
Genomic DNA was isolated using a QIAamp DNA Mini Kit (Qiagen, Valencia, CA) and was quantitated by UV absorbance measurements at 260 nm. Cross et al. (25) , were arrayed, DNA sequence-validated, and prepared for microarray as described (26) . CpG Island DNAs were printed onto chemically-activated glass slides (Dow Corning ultraGAPS slides).
CpG Island Hybridization, Washing, and Scanning
After slide rehydration, microarray slides were dried on a 95 ºC hot plate and UV crosslinked (6000μJ). Arrays were then blocked with 1% BSA, 4 × SSC, 0.5% SDS for 1 hour at 42 ºC. After blocking, slides were washed in water and treated with 0.25% NaBH in 1% SDS for 20 min at 42 ºC. Slides were washed extensively, first in 0.06 × SSC-0.01% SDS, then in 0.06 × SCC and finally in water. Targets were denatured for 10 min at 100 ºC and hybridizations were carried out in an ArrayBooster at 42 ºC for 16 hours using the Advacard AC2B according to the manufacturer instructions (The Gel Company, CA, USA). Hybridized slides were then washed with 1 × SSC-0.2% SDS for 5 min, 0.06 × SCC-0.01% SDS for 10 min, and 0.06 × SCC for 5 min at 25 ºC. Slides were dried by spinning for 1 min at 1000 rpm and then scanned on a GenePix 4000B.
Fluorescent Target Preparation
A catch-linker was ligated to the MseI fragments of genomic DNA. These fragments were then cut with a methylationspecific restriction enzyme, McrBc (New England Biolabs, Beverly, MA). "Mock-cut" samples were samples exposed to the same conditions and reagents as were the digested samples, except no GTP was added to the restriction digest. 20ng of the "mock cut" or uncut samples and 20ng McrBccut MseI-linkered genomic DNA was amplified by PCR, and the PCR products were then purified. Fluorescent Cy3 or Cy5 dye was incorporated into the PCR product using the BioPrime DNA labeling system (Invitrogen, Carlsbad, CA).
After the labeling, the cut and mock reactions were mixed together and further purified with the QIAquick PCR purification kit (Qiagen). After purification, the labeled target was lyophilized to dryness, re-suspended in 10 μl hybridization buffer (2 × SSC, 0.1% SDS, 100 ng/μl Cot1 DNA, 100 ng/μl oligo dA), denatured by boiling for 10 minutes, and added to a processed array slide. Slides were scanned for Cy3 and Cy5 fluorescence using an Axon GenePix 4000 microarray reader (Axon Instruments, Foster City, CA).
CpG Microarray Data Analysis
The data from scanned microarray images were extracted using GenePix software. The median pixel intensity of each spot and the median of local background were used for further analysis by the Excel data analysis package. To normalize Cy3 and Cy5 signal intensities we used the "interactive linear regression" approach with minor modifications (27). First, all intensity values were log transformed, then linear regression was performed only on values from the selected clones used for normalization (see below). Residuals were calculated and outliers (those residuals where |e| > 2 x standard deviation of e were removed and regression functions were recalculated. If the difference between the values of r-squared of the new regression line was less than .001 of the old regression line, then no further residuals were removed. Intercept values were applied as correction factors to the log transformed channel 2 values of all clones. The result is that the function of log channel 1 and log channel 2 of the clones closely approximates y = x. All values were then made exponential and ratios were calculated. In order to identify clones with differential fluorescence ratios that would accurately reflect relevant differences in DNA methylation or histone acetylation, a simple algorithm was employed. First, only spots with original signal intensities greater or equal to two fold local background in at least one channel were used to calculate ratios and were further analyzed. Average fluorescence ratios were calculated from normalized ratios of three independent experiments only if the percent coefficient of variation was equal to or less than 30%, allowing us to analyze only the most reproducible clones. If the clone in question passed the first two filters, then the average ratios were compared. A clone was considered differentially methylated (or unmethylated) between two populations when the difference between the average ratios was 30% or greater, as determined empirically from earlier results. The same approach was used for the identification of differentially histone H3 and H4 acetylated clones, except in this case immunoprecipitated DNA was compared to a reference DNA (input DNA isolated from the same experiment but not immunoprecipitated).
Mitochondrial DNA is unmethylated (28); therefore, signal intensity of both channels coming from mitochondrial clones are expected to be equal. Data from arrays analyzing methylation were normalized based on signals of spots containing four mitochondrial clones in four serial dilutions. These dilutions were spotted in each of four sub-arrays. Their pixel intensities covered the whole signal range of the microarray (see light blue spots Fig. 2b ). After normalization, unmethylated clones have a ratio close to 1. Ratios less than 1 reflect various levels of methylation.
Chromatin Immunoprecipitations
Chromatin immunoprecipitations using the acetyl-histone H3 and H4 antibodies were performed as described (26). Quality of the chromatin immunoprecipitations was monitored through real time PCR analysis of the GAPDH pro-moter; a highly expressed gene known to have acetylated histones associated with its promoter. Taqman primer/ probes specific for the GAPDH promoter were used and the assays were performed as previously described. Primer sequences are available upon request.
Results
Effect of the Polyamine Analog CGC-11093 on HCT116 Cell Growth and Viability
The sensitivity of HCT116 cells to CGC-11093 was assessed by analysis of cell growth and viability. For the cell growth analysis, cells were seeded in the absence or presence of different concentrations of CGC-11093, collected at days 1, 3, 5, and 7 after subculture, and the total cell number was measured using a Beckman Coulter Vi-Cel™ Cell Viability analyzer. CGC-11093 treatment resulted in significant growth inhibition of HCT116 cells in a time-and dose-dependent manner (Figure 2A ). We also tested HCT116 responses after treatment with CGC-11093 using a MTT cellular survival assay ( Figure 2B ). The MTT assay, which is based on the evaluation of the reduction of a chromophore by mitochondrial NADH-dependent succinate dehydrogenase, measures metabolic activity of living cells (29, 30) . Both methods yielded equivalent levels of drug response (~50% decrease in cell number and metabolic activity for a 72 h exposure to 10 μM CGC-11093). In order to evaluate the long-term effect of the compound on the cultured cells, we tested HCT116 cells viability after seven days in culture using a Beckman Coulter Vi-Cell™ Cell Viability analyzer. The automated analysis of 100 images of trypan blue-stained cells showed that the compound exerts cytostatic and concentration-dependent effects ( Figure 2C ).
Gene Expression Profiles of HCT116 Cells Treated with CGC-11093
The Affymetrix microarrays used in this study contain over 47,000 transcripts and variants, including 38,500 well-char- acterized human genes. We profiled the gene expression in HCT116 cells at one time point (72 h) at two different concentrations (1 and 10 μM). A comparison of the distribution of gene expression patterns revealed a greater difference in cells treated with a higher concentration of the analog. Genes differentially expressed in HCT116 cells after treatment with CGC-11093 were selected based on the one-way ANOVA test adjusted for multiple testing using the Benjamini Hochberg false discovery rate method. We have identified 1078 genes that were affected by CGC-11093 at both 1 or 10 μM in a statistically significant manner. This data set was further filtered for a 4-fold change from control cells, and 222 genes were found to be differentially expressed. The expression patterns of these genes were pro-portional to the concentration of the compound used ( Figure  3) . Classification of 222 genes based on their function revealed changes in expression of genes encoding for DNA/RNA binding transcription factors, cell cycle control, signaling, cytoskeletal, transport, and serine proteases. Selected down-or up-regulated genes whose expression was significantly changed in the Affymetrix arrays after treatment with both 1 and 10 μM of CGC-11093 are presented in Table IA and IB.
Validation of Microarray Results
We examined a group of differentially expressed genes from the microarray analysis. The differentially expressed genes evaluated by real time RT PCR showed a relative change in expression similar to that found in the array data, although their p values were higher when compared to the p values obtained from microarray analysis (Figure 4) . We confirmed the downregulation of cyclin-dependent kinase inhibitor 2C (CDKN2C). CDKN2C is the cyclin-dependent kinase inhibitor that is required for the G1 arrest that is induced by inhibiting cyclin-dependent kinase 6 during normal hematopoietic cell differentiation (31, 32). CDKN2C was found to be downregulated in a significant fraction of human medulloblastomas (33) and is associated with a poor prognosis in childhood leukemia (34). We also validated the decrease in expression of the receptor for prostaglandin E4 (PTGER4), which is putatively involved in colon PGE2-mediated carcinogenesis (35). The transcript level of MAD1, the MAX heterodimer protein, is induced by CGC-11093. It is known that MAD1-MAX dimers block most functions of MYC-MAX dimers by binding to the sequence CACGTG (E-boxes) in the regulatory region of many genes. Such binding to the key polyamine biosynthetic gene ODC leads to a suppression of cell proliferation (36, 37) . The level of serine protease genes kallikrein 6 (KLK6) and kallikrein 10 (KLK10) were induced by more than 7-and 14-fold, respectively, in treated HCT116 cells as compared to untreated cells. Secreted serine proteases, such as prostate-specific antigen (KLK3) and kallikrein 2 have been used as prostate cancer biomarkers (38). KLK6 was proposed as a potential serum marker for ureine serrous papillary cancer (39). KLK10 gene expression has recently been reported to be downregulated in the majority of breast cancer cell lines, and transfection of KLK10 into KLK10-negative cells decreased their tumorigenecity (40).
The changes in gene expression presented above demonstrate potential mechanisms of action for the antitumorigenesis effects of CGC-11093 observed in mouse models (23).
Analysis of the Pathways Associated with Genes Differentially Expressed After Treatment with CGC-11093
To identify different cellular pathways that are affected by treatment with CGC-11093, the list of 1078 genes with expression levels altered in a statistically significant manner (P<0.05) after treatment with 10 μM CGC-11093 was processed though Pathway Miner (www.biorag.org) (41). This (Table II) . Particularly, CGC-11093 causes down regulation of seven genes that promote cell cycle progression, and induces expression of the cell cycle arrest regulation genes, CDKN1A, CADD45A and B, and ATM. The combined changes in these cell cycle genes alone can account for the cytostatic effect of CGC-11093 observed in HCT116 cells. CGC-11093 also induces the expression of some aminoacyl-tRNA synthetases. In parallel, this analog decreases the expression of some proteasome subunits, RNA polymerases, and genes related to TGFβ signaling. Within the MAPK signaling, apoptosis and Wnt signaling pathways, we found genes with both upregulated and downregulated expression. 
Proteomics Analysis of CGC-11093 Effects
CGC-11093 treatment results in various changes in gene expression. To identify changes in protein expression in response to treatment with this compound, we compared the proteome of control cells with the proteome of cells treated with CGC-11093. Spots expressed exclusively on 2D PAGE gels of either control or CGC-11093 treated samples were analyzed using nanoLC-MS/MS. Proteasome subunit Y, a β-type subunit of the proteasome (42),was found only in control samples (Table III) . Tryptophanyl-t-RNA synthase, a housekeeping enzyme that attaches Tyr to the appropriate tRNA (43), was expressed exclusively in cells treated with CGC-11093. Another protein found only in treated cells was Peroxiredoxin 5, an antioxidant enzyme expressed in the peroxisome (44).
Effect of CGC-11093 on DNA Methylation and Histone Acetylation
We used 6800 element CpG island microarrays to compare the epigenomic state of untreated HCT116 cells to cells treated with 1 and 10 μM CGC-11093 under the conditions described above. Three independent experiments were performed, and the resultant microarray data was analyzed as previously described (26). CpG island microarray hybridization results showed aberrant methylation of a number of single copy CpG islands, as well as relative hypomethylation of satellite sequences in untreated HCT116 cells, consistent with earlier epigenetic analyses (45) (46) (47) (48) . When compared to CGC-11093 treated cells, no consistent and statistically significant changes in overall genomic DNA methylation could be detected. These results include single copy CpG islands, > paired-like homeodomain transcription factor 2, regulation of transcription NM_000325 Note: genes with altered expression and their known function(s) are indicated. *colors indicate the range of the change in gene expression calculated as the log of the ratio of average expression in the three arrays from CGC-11093-treated HCT116 cells to average expression in three arrays from control cells according to the following scheme: ALU sequences, and satellite sequences (data not shown).
Since the CpG island microarray employed did not have a comprehensive set of CpG island promoters arrayed on it, it remains possible that CGC-11093 affects the epigenetic state of genes that are transcriptional targets. This possibility is currently being tested through studies using microarrays spotted with over 13,000 human gene promoters.
Similarly, we also analyzed the acetylation state of histones H3 and H4 following exposure of HCT116 to 1 and 10 μM CGC-11093. DNA isolated from chromatin immunoprecipitated with either anti-acetyl H3 or H4 antibodies were fluorescently labeled and hybridized to the CpG island arrays in a ChIP on chip experimental approach. Initial results and analysis of these studies showed that less than 2% of single copy elements showed significant changes at both drug concentrations in either H3 or H4 acetylation state, nor were changes seen in the histone acetylation state in ALU or satellite sequences (data not shown). Additionally, of the changes detected in single copy sequences associated with transcriptional units, integration with the Affymetrix microarray data showed no overlap between potential histone acetylation changes and changes in gene expression. Importantly, the quality of the chromatin immunoprecipitations was monitored using real time PCR analysis of the acetylation state of the GAPDH promoter. Enrichment of immunopreciptated DNA relative to the equivalent amount of input DNA was at least 15-fold for both histones H3 and H4. Drug treatment had no demonstrable effect on the acetylation state of the GAPDH promoter. As stated above, it is possible that CGC-11093 affects the epigenetic state of genes not on the CPG island arrays, and this possibility is cur-rently being tested through studies using microarrays spotted with over 13,000 human gene promoters.
Discussion
The objective of this study was to identify signaling pathways involved in cellular responses to a specific conformationally restricted polyamine analog CGC-11093. We conducted genome wide gene expression profiling, DNA methylation and histone deacetylation analyses, and proteomic assessment of cells treated with this agent. We were able to identify agent-induced alterations in expression of a number of genes, but found that these changes were generally not associated with epigenetic modifications of either chromatin proteins or DNA. The approach of combining gene expression profiling, DNA methylation microarrays, histone acetylation, and proteomics approach can provide a powerful method for establishing detailed cellular responses to specific drug treatment.
Gene expression profiling of CGC-11093 revealed reproducible concentration-dependent changes in the expression of 222 genes. Among these genes we noted genes associated with suppression of cell cycle, transcription, and translation. We also found coordinated patterns of cellular gene expression, based on the knowledge provided for the genes and proteins in the relational database Pathway Miner from gene ontology pathways (KEGG, GenMAPP, and BioCarta). A major effect of CGC-11093 was observed in cell cycle control pathway, where treatment suppressed seven genes involved in DNA replication and in the regulation of transition through cell cycle phases, while at the same time activating the expression of four negative regulators of the cell cycle. CGC-11093 also inhibited four genes in the TGF-beta signaling pathway that are responsible for the regulation of transcription. Some similarities were found between the proteomics data and the microarray data. Proteasome subunit Y protein was not expressed in cells treated with 10 μM CGC-11093. In accordance, genes coding for other proteasome subunits (α2 subunit, β2 subunit, and the regulatory non-ATPase 11 subunit) (49) show decreased expression under the same conditions (Table II and Table III ). In addition, microarray analysis demonstrated an increase in expression of specific aminoacyl-tRNA synthetases that catalyze the transfer of amino acids to the appropriate t-RNA. This increase was shown for cysteinyl-tRNA synthetase, seryl-tRNA synthetase and alanyl-tRNA synthetase. Parallel proteomics analysis showed that tryptophanyl-t-RNA synthase was expressed only in cells treated with CGC-11093. DNA methylation and histone H3 and H4 acetylation analysis of CGC-11093-treated cells did not reveal any changes in gene methylation and histone acetylation patterns as compared to untreated cells. While this result minimizes possible epigenetic effects of this analog, other epigenetic targets exist. In summary, the performed analyses reveal that the polyamine analog CGC-11093 targets specific growth-related genes whose modulation could be a useful in anticancer therapy. The similarities found between the CGC-11093 microarray and proteomics data suggest that gene and protein expression data can show correlation when analyzed in the context of specific cellular pathways. At the same time, it is apparent that not all changes in gene expression would result in a corresponding change in the level of protein synthesis (50). Such factors as mRNA stability, translation efficiency, and proteolytic degradation can contribute to the intracellular level of proteins and can influence the biological significance of a compound's effects on gene regulation.
In conclusion, our data show that CGC-11093 affects multiple interacting cellular pathways in HCT116 colon cancer cells. Based on the presented analysis of signaling pathways influenced by CGC-11093, we could suggest the combinatory treatment of HCT116 cells with CGC-11093 and inhibitors of MAPK signaling pathway or with the inducers of apoptosis in order to amplify the observed anti-tumor effect of this drug. Our further studies will evaluate specific responses of HCT116 cells to these combinations.
